In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3200-3208

  Seifer, Maria ^a,b   Hamatake, Robert K ^a,c   Colonno, Richard J ^a   Standring, David N ^a,b  

^a BRISTOL MYERS SQUIBB   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; LOBUCAVIR;

ANIMAL CELL; ARTICLE; ENZYME INHIBITION; HEPADNAVIRUS; HEPATITIS B VIRUS; LIVER CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION; WOODCHUCK;

EID: 0031761652     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.12.3200     Document Type: Article

References (50)

1. Beasley, R. P., and L. Y. Hwang. 1991. Overview on the epidemiology of hepatocellular carcinoma, p. 532-535. In F. B. Hollinger, S. M. Lemon, and M. Margolis (ed.), Viral hepatitis and liver disease. The Williams & Willkins Co., Baltimore, Md.
2. Bisacchi, G. S., S. T. Chao, C. Bachard, J. P. Daris, S. F. Innaimo, J. A. Jacobs, O. Kocy, P. Lapointe, A. Martel, Z. Merchant, W. A. Slusarchyk, J. E. Sundeen, M. G. Young, R. J. Colonno, and R. Zahler. 1997. BMS-200475, a novel carbocyclic 2′-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro. Bioorg. Med. Chem. Lett. 7: 127-132.
3. Civitico, G., T. Shaw, and S. Locarnini. 1996. Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro. Antimicrob. Agents Chemother. 40:1180-1185.
4. Clark, J. M. 1997. Unpublished data.
5. Dannaoui, E., C. Trépo, and F. Zoulim. 1997. Inhibitory effect of penciclovirtriphosphate on duck hepatitis B virus reverse transcription. Antivir. Chem. Chemother. 8:38-46.
6. Davis, M. G., J. E. Wilson, N. A. VanDraanen, W. H. Miller, G. A. Freeman, S. M. Daluge, F. L. Boyd, A. E. Aulabaugh, G. R. Painter, and L. R. Boone. 1996. DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs. Antivir. Res. 30:133-145.
7. Dean, J., S. Bowden, and S. Locarnini. 1995. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antivir. Res. 27:171-178.
8. Dienstag, J. L., R. P. Perillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
9. Field, A. K., A. V. Tuomari, B. McGeever-Rubin, B. J. Terry, K. E. Mazina, M. L. Haffey, M. E. Hagen, J. M. Clark, A. Braitman, W. A. Slusarchyk, M. G. Young, and R. Zahler. 1990. (±)-(1 alpha,2 beta,3 alpha)-9-[2,3-Bis(hydroxymethyl)-cyclobutyl] guanine [(±)-BHCG or SQ 33,054]: a potent and selective inhibitor of herpesviruses. Antivir. Res. 13:41-52.
10. Galibert, F., E. Mandart, F. Fitoussi, P. Tiollais, and P. Charnay. 1979. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 281:646-650.
11. Ganem, D., J. R. Pollack, and J. Tavis. 1994. Hepatitis B virus reverse transcriptase and its many roles in hepadnavirus genomic replication. Infect. Agents Dis. 3:85-93.
12. Garnier, J.-L., P. Chossegros, S. Daoud, P. Chevallier, J.-M. Dubernard, C. Trepo, and J.-L. Touraine. 1997. Treatment of hepatitis B virus replication by ganciclovir in kidney transplant patients. Transplant. Proc. 29:817.
13. Genovesi, E. V., L. Lamb, I. Medina, D. Taylor, M. Seifer, S. Innaimo, R. J. Colonno, D. N. Standring, and J. M. Clark. 1998. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. 42:3209-3217.
14. Honkoop, P., and R. A. deMan. 1995. Clinical aspects of nucleoside analogues for chronic hepatitis B. Int. Antivir. News 3:78-80.
15. Horwich, A. L., K. Furtak, J. Pugh, and J. Summers. 1990. Synthesis of hepadnavirus particles containing replication-defective duck hepatitis B virus genomes in cultured Huh-7 cells. J. Virol. 64:642-650.
16. Howe, A. Y., M. J. Robins, J. S. Wilson, and D. L. Tyrrell. 1996. Selective inhibition of the reverse transcriptase of duck hepatitis B virus by binding of 2′,3′-dideoxyguanosine 5′-triphosphate to the viral polymerase. Hepatology 23:87-96.
17. Innaimo, S. F., M. Seifer, G. S. Bisacchi, D. N. Standring, R. Zahler, and R. J. Colonno. 1997. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 41:1444-1448.
18. Jacobs, G. A., J. A. Tino, and R. Zahler. 1989. Synthesis of SQ-32,829, a new nucleoside antiviral agent. Tetrahedron Lett. 30:6955-6958.
19. Korba, B. E., and M. R. Boyd. 1996. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob. Agents Chemother. 40:1282-1284.
20. Lanford, R. E., L. Notvall, H. Lee, and B. Beames. 1997. Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase. J. Virol. 71:2996-3004.
21. Lanford, R. E., L. Notvall, and B. Beames. 1995. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. J. Virol. 69:4431-4439.
22. Lien, J. M., C. E. Aldrich, and W. S. Mason. 1986. Evidence that a capped oligoribonucleotide is the primer for duck hepatitis B virus plus-strand synthesis. J. Virol. 57:229-236.
23. Locarnini, S. A., G. M. Civitico, and J. E. Newbold. 1996. Hepatitis B: new approaches for antiviral chemotherapy. Antivir. Chem. Chemother. 7:53-64.
24. Löfgren, B., E. Nordenfelt, and B. Oeberg. 1989. Inhibition of RNA- and DNA-dependent duck hepatitis B virus DNA polymerase activity by nucleoside and pyrophosphate analogs. Antivir. Res. 12:301-310.
25. Miller, R., P. Marion, and W. Robinson. 1984. Hepatitis B viral DNA-RNA hybrid molecules in particles from infected liver are converted to viral DNA molecules during an endogenous DNA polymerase reaction. Virology 139: 64-72.
26. Molnar-Kimber, K. L., J. Summers, J. M. Taylor, and W. S. Mason. 1983. Protein covalently bound to minus-strand DNA intermediates of duck hepatitis B virus. J. Virol. 45:165-172.
27. Nassal, M., and A. Rieger. 1996. A bulged region of the hepatitis B virus RNA encapsidation signal contains the replication origin for discontinuous first-strand DNA synthesis. J. Virol. 70:2764-2773.
28. Nevens, F., J. Main, P. Honkoop, D. L. Tyrrell, J. Barber, M. T. Sullivan, J. Fevery, R. A. De Man, and H. C. Thomas. 1997. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 113:1258-1263.
29. Price, P. M., R. Banerjee, A. M. Jeffrey, and G. Acs. 1992. The mechanism of inhibition of hepatitis B virus replication by the carbocyclic analog of 2′-deoxyguanosine. Hepatology 16:8-12.
30. Radziwill, G., W. Tucker, and H. Schaller. 1990. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J. Virol. 64:613-620.
31. Sanger, F., S. Nicklen, and A. R. Coulson. 1992. DNA sequencing with chain-terminating inhibitors. Bio/Technology 24:104-108.
32. Schlam, S. W., R. A. Heytink, H. R. Van Buuren, and R. A. De Man. 1986. Acylovir, oral, intravenous and combined with interferon for chronic HBeAg-positive hepatitis. J. Hepatol. 3(Suppl. 2):S137-S141.
33. Seeger, C., J. Summers, and W. S. Mason. 1991. Viral DNA synthesis. Curr. Top. Microbiol. Immunol. 168:41-59.
34. Segel, I. H. 1975. Enzymes, p. 208-323. In Biochemical calculations. John Wiley & Sons, Inc., New York, N.Y.
35. Seifer, M., R. K. Hamatake, M. Bifano, and D. N. Standring. 1998. Generation of replication-competent hepatitis B virus nucleocapsids in insect cells. J. Virol. 72:2765-2776.
36. Severini, A., X. Y. Liu, J. S. Wilson, and D. L. Tyrrell. 1995. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2′,3′-dideoxy3′-thiacytidine. Antimicrob. Agents Chemother. 39:1430-1435.
37. Slusarchyk, W. A., A. K. Field, J. A. Greytok, P. Taunk, A. V. Tooumari, M. G. Young, and R. Zahler. 1992. 4-Hydroxy-3-(hydroxymethyl)-2-methylcyclopentyl purines and pyrimidines, a novel class of anti-herpesvirus agents. Antivir. Res. 17(Suppl. 1):98. (Abstract.)
38. Staschke, K. A., and J. M. Colacino. 1994. Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5′-triphosphate of fialuridine. J. Virol. 68:8265-8269.
39. Summers, J., and W. S. Mason. 1982. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29:403-415.
40. Tavis, J. E., and D. Ganem. 1996. Evidence for activation of the hepatitis B virus polymerase by binding of its RNA template. J. Virol. 70:5741-5750.
41. Tavis, J. E., S. Perri, and D. E. Ganem. 1994. Hepadnaviral reverse transcription initiates within a stem-loop of the RNA packaging signal and employs a novel strand transfer. J. Virol. 68:3536-3543.
42. Tencza, M. G., and J. E. Newbold. 1997. Heterogeneous response for mammalian hepadnavirus infection to acyclovir: drug arrested intermediates of minus strand viral DNA are enveloped and secreted from infected cells as virion-like particles. J. Med. Virol. 51:6-16.
43. Terry, B. J., K. E. Mazina, A. V. Tuomari, M. L. Haffey, M. Hagen, A. Feldman, W. A. Slusarchyk, M. G. Young, R. Zahler, and A. K. Field. 1988. Broad-spectrum antiviral activity of the acyclic guanosine phosphonate (R,S)-HPMPG. Antivir. Res. 10:235-252.
44. Terry, B. J., K. E. Mazina, A. V. Tuomari, M. E. Hagen, M. L. Haffey, G. A. Jacobs, R. Zahler, and A. K. Field. 1990. Anti-herpetic activity of (±)-(1a,2b,3a)-9-[2-hydroxy-3-(hydroxymethyl)cyclobutyl]guanine and inhibition of HSV-1 DNA polymerase. Antivir. Chem. Chemother. 1:263-268.
45. Wang, G. H., and C. Seeger. 1993. Novel mechanism for reverse transcription in hepatitis B viruses. J. Virol. 67:6507-6512.
46. Wang, G. H., and C. Seeger. 1992. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 71:663-670.
47. Yamada, M., M. Ishii, M. Miura, S. Sato, A. Kanno, H. Ohori, and T. Toyota. 1993. Three distinct Southern blot hybridization patterns of HBV-DNA in the sera of HBV carriers. Tohoku J. Exp. Med. 170:219-228.
48. Yang, H. Y., R. L. Drain, C. A. Franco, and J. M. Clark. 1996. Efficacy of BMS-180194 against experimental cytomegalovirus infections in immudocompromised mice. Antivir. Res. 29:233-241.
49. Zoulim, F. 1997. Improving hepatitis B virus therapy - new inhibitors of reverse transcriptase. Int. Antivir. News 5:110-112.
50. Zoulim, F., and C. Seeger. 1994. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J. Virol. 68:6-13.